2.

Univariate and multivariate analyses of PFS

Characteristics	Univariate analysis			Multivariate analysis
	HR (95% CI)	P		HR (95% CI)	P
PFS, progression-free survival; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; SUVmax, the maximum standardized uptake values; SUVmean, mean standardized uptake values; MTV, metabolic tumor volume; TLG, total lesion glycolysis; HR, hazard ratio; 95% CI, 95% confidence interval.
Age (<60vs. ≥60 years)	1.29 (0.79−2.09)	0.300
Sex (male vs. female)	1.00 (0.56−1.77)	0.992
Lauren’s classification (diffused vs. undiffused)	1.11 (0.63−1.93)	0.721
Lymph node metastasis (no vs. yes)	2.74 (1.31−5.74)	0.004		2.16 (1.01−4.65)	0.048
T stage (T2/T3 vs. T4)	1.71 (1.17−2.50)	0.001		1.89 (1.11−3.16)	0.020
Histologic grade (poorly and moderately-poorly vs. moderately)	0.64 (0.35−1.18)	0.145
Neoadjuvant chemotherapy (no vs. yes)	1.34 (0.82−2.19)	0.240
Surgery (subtotal gastrectomy vs. total gastrectomy)	1.32 (0.83−2.12)	0.238
Lymph node dissection (D1 vs. D0)	2.05 (0.93−4.48)	0.065
HER2 expression (positive vs. negative)	0.80 (0.46−1.39)	0.421
Ki-67 expression (≥75% vs. <75%)	1.02 (0.61−1.73)	0.936
c-Met expression (positive vs. negative)	0.40 (0.33−1.37)	0.262
EGFR expression (positive vs. negative)	1.09 (0.64−1.84)	0.746
SUVmax (<10.9vs. ≥10.9)	0.69 (0.33−1.47)	0.310
SUVmean (<5.9vs. ≥5.9)	0.60 (0.26−1.38)	0.215
MTV (<15.1 cm3 vs. ≥15.1 cm3)	1.67 (1.03−2.71)	0.033		1.13 (0.46−2.82)	0.789
TLG (<47.3 cm3 vs. ≥47.3 cm3)	1.70 (1.04−2.79)	0.032		1.96 (0.90−4.27)	0.502